Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
155 hedge funds and large institutions have $1.08B invested in Intercept Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 64 increasing their positions, 38 reducing their positions, and 42 closing their positions.
68% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 38
24% more call options, than puts
Call options by funds: $117M | Put options by funds: $94.1M
7% less funds holding
Funds holding: 167 → 155 (-12)
21% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 42
57% less capital invested
Capital invested by funds: $2.5B → $1.08B (-$1.42B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Senvest Management
New York
|
+$62.9M |
| 2 |
JP Morgan Chase
New York
|
+$41.8M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$29.4M |
| 4 |
JG
Jefferies Group
New York
|
+$27.7M |
| 5 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$24.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
-$246M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$121M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$59.7M |
| 4 |
O
OrbiMed
New York
|
-$50.6M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$25M |
ICPT Hedge Fund Activity: Q3 2017 in Review
155 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q3 2017, worth a combined $1.08B — down 57% from $2.5B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of ICPT and 33 opened new positions — a net loss of 9 holders — while 38 trimmed existing stakes and 64 added.
The largest buyer was Senvest Management, opening a new position worth an estimated $62.9M. The largest seller was Carmignac Gestion, exiting entirely with an estimated $246M sold.
- 155 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q3 2017, down from 167 in Q2 2017.
- Funds reported $1.08B of Intercept Pharmaceuticals, Inc. stock for Q3 2017, down 57% quarter-over-quarter.
- 33 funds opened new Intercept Pharmaceuticals, Inc. positions in Q3 2017 and 42 closed out, a net change of -9 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q3 2017 was Senvest Management, an estimated $62.9M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q3 2017 was Carmignac Gestion, an estimated $246M sold.
Based on aggregated 13F filings for Q3 2017.